Her Royal Highness The Princess Royal Officially Opens Insmed’s New Research and Development Facility in Cambridge, UK

Her Royal Highness The Princess Royal Officially Opens Insmed’s New Research and Development Facility in Cambridge,

UK LONDON, Friday 18 July 2025, Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today welcomes the opening of a new research and development (R&D) facility in Cambridge, UK, by Her Royal Highness The Princess Royal. With the new site focused on synthetic rescue for serious diseases, Insmed expands its UK-based R&D presence in Cambridge.

During the visit, The Princess Royal was greeted by Will Lewis, Chair and CEO of Insmed, who escorted her on a tour of the site where she met some of the company’s scientists and learned about their work.

“We are immensely proud to show The Princess Royal around our research site,” Lewis said. “The work we are doing in Cambridge is central to our research and development at Insmed and has the potential to deliver much-needed therapies for patients with serious diseases globally.”

The state-of-the art 17,000 square foot facility, located on the city’s Babraham Research Campus, underscores Insmed’s commitment to delivering first- and best-in-class therapies that will transform the lives of people with serious diseases. The work being done at the new site contributes to the UK’s global position in biotechnology innovation.

"We are at a pivotal moment where new insights into the biology and genetics of serious diseases are opening new possibilities to identify and develop impactful treatments for conditions that still have few or no effective options,” said Dr Tom Heightman, SVP of Research at Insmed. “Our work in synthetic rescue was developed in Cambridge and the opening of this site marks an exciting new chapter in our relationship with this region and across the broader life sciences industry here in the UK.”

The Insmed Cambridge team is leveraging the company’s pioneering synthetic rescue platform. This leading platform has the potential to identify targets outside the disrupted biological pathway that, when modulated, may restore health. This scalable platform couples cutting-edge molecular and cell biology techniques with sophisticated analysis of human genetics datasets to potentially deliver powerful new ways of treating a broad range of serious diseases. This technology has the potential to correct the impact of underlying gene defects and help damaged cells recover from certain disease imbalances.

The new location allows for close collaboration between R&D specialities under one roof to promote highly effective development processes from target discovery, to drug discovery and translational science. The Cambridge R&D team will continue to work closely with Insmed's other research sites in New Jersey, New Hampshire and San Diego in the US.